Loading...
•
Mar 31, 2024
Corbus Pharmaceuticals Q1 2024 Earnings Report
Reported financial results for the first quarter of 2024 and provided a corporate update.
Key Takeaways
Corbus Pharmaceuticals reported a net loss of $6.9 million for Q1 2024. The company dosed the first patient in the U.S. Phase 1 clinical trial of CRB-701 and expects to dose the first patient in the CRB-913 Phase 1 study in Q1 2025. They also raised $116 million in capital, extending their cash runway through Q1 2027.
Dosed first patient in U.S. Phase 1 clinical trial of CRB-701.
Expect to dose first patient in CRB-913 Phase 1 study in Q1 2025.
Raised $116 million in Q1 2024, extending cash runway through Q1 2027.
Appointed Dr. Dominic Smethurst as Chief Medical Officer.
Forward Guidance
Corbus Pharmaceuticals expects to continue advancing its programs across its pipeline.
Positive Outlook
- CRB-701 U.S. dose escalation data is expected to be presented by Q1 2025.
- CRB-913 is expected to dose the first patient in the Phase 1 study in Q1 2025.
- Phase 1 study of CRB-601 is expected to initiate in the summer of 2024.
- Cash runway extended through Q1 2027.
- Advancing pipeline toward meaningful milestones.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...